T-DXd combined with Sotorasib showed promising efficacy in preclinical studies of KRAS G12C-mutant non-small cell lung cancer – Oncodaily
T-DXd combined with Sotorasib showed promising efficacy in preclinical studies of KRAS G12C-mutant non-small cell lung cancer.
Full Article Content
T-DXd Plus Sotorasib in KRAS G12C-Mutant NSCLC showed durable preclinical tumor regressions and highlighted HER2 testing gaps. , ADCs, Antibody drug conjugates, HER2, HER2 expression, HER2 IHC, KRAS G12C, KRAS G12C-mutant NSCLC, KRAS inhibitor resistance, Lung cancer, NSCLC, OncoDaily Lung, Precision Oncology, preclinical oncology, Sotorasib, T-Dxd, targeted therapy, Thoracic Oncology, Trastuzumab deruxtecan, xenograft models
Products Mentioned in This Article
These products were automatically matched from the article title, summary, and full content.
Frequently Asked Questions
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Sotorasib – Buy online、SOTOLDX Sotorasib 120mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.